Literature DB >> 7818811

Genotypic subtypes of HIV-1 in Cameroon.

J N Nkengasong1, W Janssens, L Heyndrickx, K Fransen, P M Ndumbe, J Motte, A Leonaers, M Ngolle, J Ayuk, P Piot.   

Abstract

OBJECTIVE: The only two HIV-1 strains (ANT70 and MVP5180) reported to date from Cameroon are members of the outlier clade (group O). In this study, we assessed the prevalence of group O viruses and other HIV-1 subtypes in Cameroon.
DESIGN: A phylogenetic analysis of 18 HIV-1 strains isolated from seropositive individuals from Yaoundé and Douala, Cameroon.
METHODS: A 900 base-pair fragment of the env gene coding for V3, V4, V5, and the beginning of gp41 of 17 out of 18 HIV-1 isolates from Cameroon was amplified, cloned and sequenced using polymerase chain reaction. A phylogenetic tree was constructed.
RESULTS: The overall env nucleotide sequence divergence among the Cameroon isolates ranged from 6.1 to 27.5%. In a phylogenetic tree, six subtypes were identified when compared with 23 reference strains of different geographic origin. Of these 17 Cameroonian strains, 11 (61%) were of subtype A of which the interpatient distances at the sequence level varied from 6.1% to 18.3% (average, 11.9%). Three (17%) strains were of subtype F, and the other three strains (6% each) belonged to subtypes B, E and H, respectively. The remaining isolate was classified as belonging to group O, on the basis of the sequence of part of the pol gene. A very broad spectrum of different tetrameric amino-acid sequences was observed at the apex of the V3 loop. Eleven strains contained the tetrameric globally predominant GPGQ sequence at the tip of the V3 motif. Two strains had the GPGR sequence typical of the American and European HIV-1 strains. The remaining tetrameric sequences included GPGS, GSGQ, GRGQ, and GLGR.
CONCLUSION: These findings on a limited number of viruses suggest extensive env gene diversity of HIV-1 strains from Cameroon, and could have implications for vaccine development in Africa.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Biology; Cameroon; Developing Countries; Diseases; Examinations And Diagnoses; French Speaking Africa; Genetics; Hiv; Hiv Infections; Laboratory Examinations And Diagnoses; Laboratory Procedures; Middle Africa; Research Report; Viral Diseases

Mesh:

Substances:

Year:  1994        PMID: 7818811     DOI: 10.1097/00002030-199410000-00006

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  35 in total

1.  Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV.

Authors:  S Zolla-Pazner; M K Gorny; P N Nyambi; T C VanCott; A Nádas
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Identification and genetic characterization of a novel CRF22_01A1 recombinant form of HIV type 1 in Cameroon.

Authors:  Jiangqin Zhao; Shixing Tang; Viswanath Ragupathy; Jean K Carr; Nathan D Wolfe; Bih Awazi; Indira Hewlett
Journal:  AIDS Res Hum Retroviruses       Date:  2010-09       Impact factor: 2.205

3.  Simplified strategy for detection of recombinant human immunodeficiency virus type 1 group M isolates by gag/env heteroduplex mobility assay. Study Group on Heterogeneity of HIV Epidemics in African Cities.

Authors:  L Heyndrickx; W Janssens; L Zekeng; R Musonda; S Anagonou; G Van der Auwera; S Coppens; K Vereecken; K De Witte; R Van Rampelbergh; M Kahindo; L Morison; F E McCutchan; J K Carr; J Albert; M Essex; J Goudsmit; B Asjö; M Salminen; A Buvé; G van Der Groen
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Langerhans cell tropism of human immunodeficiency virus type 1 subtype A through F isolates derived from different transmission groups.

Authors:  M T Dittmar; G Simmons; S Hibbitts; M O'Hare; S Louisirirotchanakul; S Beddows; J Weber; P R Clapham; R A Weiss
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  Relative reactivity of the V3 loop PND of HIV-1 subtypes A, B, C, D, and F with sera from selected Ugandan localities.

Authors:  J P Riley; G A Pestano; K Hosford; C Francis; J M Xie; P Mugyenyi; P Kataaha; E Katongole-Mbidde; W W Anokbonggo; J Guyden
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

6.  Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility.

Authors:  C Apetrei; D Descamps; G Collin; I Loussert-Ajaka; F Damond; M Duca; F Simon; F Brun-Vézinet
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

7.  Molecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in Italy.

Authors:  Nazle Mendonca Collaço Véras; Maria Mercedes Santoro; Rebecca R Gray; Andrew J Tatem; Alessandra Lo Presti; Flaminia Olearo; Giulia Cappelli; Vittorio Colizzi; Desiré Takou; Judith Torimiro; Gianluca Russo; Annapaola Callegaro; Romina Salpini; Roberta D'Arrigo; Carlo-Federico Perno; Maureen M Goodenow; Massimo Ciccozzi; Marco Salemi
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-06       Impact factor: 2.205

8.  Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational features.

Authors:  Peter N Fonjungo; Eitel N Mpoudi; Judith N Torimiro; George A Alemnji; Laura T Eno; Esther J Lyonga; John N Nkengasong; Renu B Lal; Mark Rayfield; Marcia L Kalish; Thomas M Folks; Danuta Pieniazek
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

9.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa.

Authors:  F E McCutchan; A W Artenstein; E Sanders-Buell; M O Salminen; J K Carr; J R Mascola; X F Yu; K E Nelson; C Khamboonruang; D Schmitt; M P Kieny; J G McNeil; D S Burke
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.